Heart Failure

In this video exclusive, Richard E. Pratley, MD, talks with Deepak L. Bhatt, MD, MPH, about results and implications of the SOLOIST and SCORED trials of the SGLT1/SGLT2 inhibitor sotogliflozin vs. placebo in adults with type 2 diabetes.

During the peak of the COVID-19 pandemic, there was a significant delay for patients presenting with acute MI to seek medical care, which may be linked to a spike in rehospitalization for HF at 6 months, researchers reported.

Abiomed announced its right heart pump has received FDA premarket to treat acute right HF for up to 14 days.

Patients with HF had elevated risk for various cancer diagnoses vs. those without HF, especially cancers of the head and neck and respiratory organs.

In a prospective cohort study of patients hospitalized with HF with preserved ejection fraction, a majority of participants had evidence of epicardial CAD, coronary microvascular disease or both.

Compared with a cohort free of kidney disease, patients with primary nephrotic syndrome were nearly 20-times more likely to develop kidney failure within 4.5 years of follow-up, research showed.

Sotagliflozin increased the number of days alive and out of the hospital compared with placebo among patients with type 2 diabetes at high risk for intermittent hospitalization due to worsening heart failure, data show.

The American Diabetes Association issued updates to the 2021 Standards of Medical Care in Diabetes to reflect new data on the immunotherapy teplizumab for type 1 diabetes and heart failure benefits seen with SGLT2 inhibitors.

An early, tailored rehabilitation program for patients who had been hospitalized with acute HF.

Sacubitril/valsartan (Entresto, Novartis) vs. ramipril for prevention of HF events in patients with MI.